BNP Paribas Asset Management
HRMY icon

BNP Paribas Asset Management’s Harmony Biosciences HRMY Stock Holding History

BNP Paribas Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.93M Sell
69,025
-455
-0.7% -$14.9K ﹤0.01% 1081
2025
Q4 		$2.6M Buy
69,480
+69,117
+19,040% +$2.27M ﹤0.01% 1011
2025
Q3 		$10K Hold
363
– – ﹤0.01% 1634
2025
Q2 		$11K Buy
+363
New +$11.7K ﹤0.01% 1734

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BNP Paribas Asset Management's HRMY Position: Q1 2026 in Review

BNP Paribas Asset Management reduced its Harmony Biosciences (HRMY) stake by 0.65% in Q1 2026, selling an estimated $14.9K and leaving 69,025 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1081.

BNP Paribas Asset Management first reported a position in HRMY in Q2 2025 and has held it in 4 quarters since. The position peaked at $2.6M in Q4 2025. 310 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • BNP Paribas Asset Management held 69,025 shares of Harmony Biosciences worth $1.93M as of Q1 2026.
  • BNP Paribas Asset Management sold 455 Harmony Biosciences shares in Q1 2026, an estimated $14.9K.
  • Harmony Biosciences made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #1081 holding.
  • BNP Paribas Asset Management first reported a position in Harmony Biosciences in Q2 2025 and has held it in 4 quarters since.
  • BNP Paribas Asset Management's Harmony Biosciences position peaked at $2.6M in Q4 2025.
  • 310 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.